MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy
Fey R, Nichols R, Tran T, Vandenbark A, Kulkarni R. MIF and CD74 as Emerging Biomarkers for Immune Checkpoint Blockade Therapy. Cancers 2024, 16: 1773. PMID: 38730725, PMCID: PMC11082995, DOI: 10.3390/cancers16091773.Peer-Reviewed Original ResearchImmune-related adverse eventsImmune-related adverse events developmentResponse to ICB therapyImmune checkpoint blockade therapyImmune checkpoint blockadePredictive biomarkersICB therapyCheckpoint blockade therapySerum MIF levelsBlockade therapyCheckpoint blockadeMIF levelsMalignant melanomaTreatment resistanceSolid tumorsAdverse eventsAutoimmune diseasesContext of cancerPrognostic biomarkerCancer progressionCognate receptor CD74Receptor CD74TherapyCD74CancerVascular mimicry as a facilitator of melanoma brain metastasis
Provance O, Oria V, Tran T, Caulfield J, Zito C, Aguirre-Ducler A, Schalper K, Kluger H, Jilaveanu L. Vascular mimicry as a facilitator of melanoma brain metastasis. Cellular And Molecular Life Sciences 2024, 81: 188. PMID: 38635031, PMCID: PMC11026261, DOI: 10.1007/s00018-024-05217-z.Peer-Reviewed Original ResearchConceptsVascular mimicryBrain metastasesMouse model of metastatic melanomaIncreased risk of metastasisAssociated with tumor volumeMelanoma brain metastasesRisk of metastasisSurvival of miceFuture treatment regimensCell line modelsTumor suppressor pathwayMetastatic melanomaTumor volumeSolid tumorsTreatment regimensTumor typesPoor prognosisHippo tumor suppressor pathwayIncreased riskMouse modelDownstream targets YAPMelanomaMetastasisSuppressor pathwayTumor